A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S)

Psoriasis, a chronic immune-mediated disease, is associated with an increased risk of cardiovascular events and mortality. Secukinumab selectively neutralizes IL-17A and has reported high efficacy with a favorable safety profile in various psoriatic disease manifestations. Subsequent to the 12-week...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of investigative dermatology 2020-09, Vol.140 (9), p.1784-1793.e2
Hauptverfasser:	Gelfand, Joel M., Shin, Daniel B., Duffin, Kristina Callis, Armstrong, April W., Blauvelt, Andrew, Tyring, Stephen K., Menter, Alan, Gottlieb, Scott, Lockshin, Benjamin N., Simpson, Eric L., Kianifard, Farid, Sarkar, Rajendra Prasad, Muscianisi, Elisa, Steadman, Jennifer, Ahlman, Mark A., Playford, Martin P., Joshi, Aditya A., Dey, Amit K., Werner, Thomas J., Alavi, Abass, Mehta, Nehal N.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Aorta - diagnostic imaging Aorta - drug effects Aorta - immunology Arteritis - blood Arteritis - diagnosis Arteritis - drug therapy Arteritis - immunology Biomarkers - blood Double-Blind Method Female Fluorodeoxyglucose F18 Humans Interleukin-17 - antagonists & inhibitors Interleukin-17 - immunology Male Metabolic Syndrome - blood Metabolic Syndrome - diagnosis Metabolic Syndrome - immunology Metabolic Syndrome - prevention & control Middle Aged Placebos - administration & dosage Placebos - adverse effects Positron Emission Tomography Computed Tomography Psoriasis - blood Psoriasis - complications Psoriasis - drug therapy Psoriasis - immunology Severity of Illness Index Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!